Default company panoramic image
Logo

Medical Nanotechnologies

We are revolutionizing the way cancer is treated by developing nanoparticle-based therapies to directly kill cancer cells using heat.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Irving, TX, USA
  • Currency USD
  • Founded May 2007
  • Employees 1
  • Website nanomedinc.com

Company Summary

Our primary products lines under development are non-invasive, localized hyperthermic therapies for cancer patients with solid tumors. Our core platform is based on nanoparticles which can be delivered to the tumor, engulfed by targeted cancer cells, and irradiated by near-infrared (NIR) light. Upon NIR irradiation, the nanoparticles rapidly heat up, directly killing the targeted tumor cells and eliminating the tumor's ability to adapt and recur.

Team

  • Default avatar
    Gareth Hughes
    President and CEO, co-founder

    Dr. Gareth Hughes is a biomedical engineer who has been involved with micro- and nanotechnology for lifesciences since 1994 and has helped start or grow 4 medtech/biotech startups. Dr. Hughes holds a B.S. in Chemical Engineering from the University of Cincinnati, a Ph.D. in Biomedical Engineering from the University of Minnesota and an M.B.A. from the University of Dallas. He is well-versed in non-dilutive funding, winning $10MM in grants.

  • Default avatar
    Rob Burgess
    Chairman of the Board, co-founder

    Dr. Rob Burgess is Director of Business Development for RayBiotech, Inc. He previously held the positions of Vice President, Business Development for the U.K.-based firm Stem Cell Sciences, LLC and Vice President, Research and Development for Zyvex Corporation. Dr. Burgess holds a B.A. in Biochemistry from the University of Texas at Austin and a Ph.D. in Molecular Biology from the University of Texas, M.D. Anderson Cancer Center.

  • Default avatar
    Rockford Draper
    Scientific Advisor, co-founder

    Dr. Rockford Draper is a professor at the University of Texas at Dallas with joint appointments in the Department of Molecular & Cell Biology and the Chemistry Department and is a member of the NanoTech Institute. He obtained his BA in chemistry from the University of Washington and his Ph.D. in biochemistry from the University of California at Los Angeles.

  • Default avatar
    Ellen Vitetta
    Scientific Advisor, co-founder

    Dr. Ellen Vitetta is Director of the Cancer Immunobiology Center at UT Southwestern Medical Center at Dallas. She has published 475 papers, edited several books, and is a co-inventor on 13 issued patents. Over the past two decades, she has developed antibody-based “biological missiles” (immunotoxins) to destroy cancer cells. These novel therapeutics have been evaluated in >300 humans. She is the PI on 10 FDA INDs for clinical trials.

  • Default avatar
    Paul Pantano
    Scientific Advisor

    Dr. Paul Pantano is an Associate Professor of Analytical Chemistry at The University of Texas at Dallas and is a member of the NanoTech Institute. He has published over forty scientific papers and is a co-inventor on three patents. Dr. Pantano was awarded his B.S. in Chemistry from the University of California at Los Angeles and his Ph.D. in Analytical Chemistry from the University of California at Riverside.

  • Default avatar
    Tom Klein
    Business Development Advisor

    Tom Klein has served as the acting CFO of two private startup biotechnology companies, Spine Wave, Inc and Rib-X Pharmaceuticals, Inc. Rib-X was funded through a $21.85 million Series A round of financing, probably the largest for U.S. biotechs in 2001, then closed a $52 million Series B round in 2003. He was also Director of Finance and Treasurer of Novo Nordisk of North America, Inc., a holding company for the NYSE-listed Novo Nordisk A/S.

Previous Investors

  • Default avatar
    None
    Unconfirmed